Company Navidea Biopharmaceuticals, Inc.
Equities
NAVB
US63937X2027
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.035 USD | -8.14% | -20.45% | -36.59% |
Business Summary
Number of employees: 13
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Diagnostics
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.65% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
77.7
%
| 0 | 16.6 % | 0 | 77.7 % | -42.04% |
Europe
21.4
%
| 0 | 8.6 % | 0 | 21.4 % | -69.23% |
Australia
0.9
%
| - | - | 0 | 0.9 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 28/23/28 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Richard McFerron
LAW | General Counsel | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 30/22/30 |
John Scott
BRD | Director/Board Member | 69 | 08/21/08 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 01/23/01 |
Dana Moss
BRD | Director/Board Member | 47 | 11/23/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,270 | 0 | 0 | 64.11 % |
Stock B | 1 | 100,084,385 | 64,162,385 ( 64.11 %) | 0 | |
Stock C | 0 | 3,596 | 0 | 0 |
Company contact information
Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue Suite 240
43017-3552, Dublin
+614 793 7500
http://www.navidea.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-36.59% | 3.81M | |
+2.47% | 42.75B | |
+47.70% | 41.61B | |
+11.94% | 41.34B | |
-8.83% | 26.59B | |
+7.33% | 25.49B | |
-22.70% | 18.12B | |
+30.49% | 12.24B | |
-2.06% | 11.76B | |
+9.22% | 11B |
- Stock Market
- Equities
- NAVB Stock
- Company Navidea Biopharmaceuticals, Inc.